Design Therapeutics, Inc. (DSGN)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Design Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 2.59M | $26.05M | $35M | $8.95M | 34.37% |
 Point72 Asset Management LP Point72 Asset Management LP | 2.72M | $24.26M | $36.38M | $12.12M | 49.97% |
 Joseph Castro Nuveen LLC | 126,815 | $500,048.74 | $1.69M | $1.19M | 238.25% |
 Li Peng China Universal Asset Management Co. Ltd. | 35,109 | $252,262.02 | $473,795.95 | $221,533.93 | 87.82% |
| RG Robert Glass AlphaCentric Advisors LLC | 21,231 | $200,367.72 | $282,457.22 | $82,089.5 | 40.97% |
Design Therapeutics, Inc. (DSGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Design Therapeutics, Inc. ever had a stock split?
Design Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Pratik Shah CEO | NASDAQ (NGS) Exchange | 25056L103 CUSIP |
| US Country | 124 Employees | - Last Dividend | - Last Split | 26 Mar 2021 IPO Date |
Overview
Design Therapeutics, Inc. is a forward-looking biopharmaceutical company situated in Carlsbad, California. Since its incorporation in 2017, the company has distinguished itself in the highly competitive pharmaceutical landscape through its dedicated pursuit of creating, developing, and commercializing small molecule therapeutic drugs. These efforts are squarely aimed at treating genetic diseases within the United States, marking a significant advancement in the field of genetics-based medicine. At the heart of Design Therapeutics’ innovative approach is its proprietary GeneTAC platform. This advanced technological platform is instrumental in the design and development of therapeutic candidates, particularly targeting inherited diseases caused by nucleotide repeat expansion—a common but complex challenge in genetics. Through its groundbreaking work, Design Therapeutics, Inc. not only embodies the cutting edge of biopharmaceutical research but also offers a beacon of hope for individuals afflicted with genetic diseases.
Products and Services
- Friedreich Ataxia
- Myotonic Dystrophy Type-1
- Fuchs Endothelial Corneal Dystrophy
- Huntington's Disease
As part of its ambitious drug development pipeline, Design Therapeutics, Inc. is focusing on a potentially disease-modifying treatment for Friedreich Ataxia. This inherited condition is a monogenic, autosomal recessive disease, characterized by progressive multi-system degeneration. Those affected by it suffer from complications relating to organs dependent on mitochondrial function, leading to neurological, cardiac, and metabolic dysfunction. The therapeutic candidate for Friedreich Ataxia stands as a vital component of the company's mission to address severe genetic disorders at their root cause.
Another leading drug candidate from Design Therapeutics targets Myotonic Dystrophy Type-1. This condition is a dominantly-inherited, monogenic progressive neuromuscular disease. It predominantly affects the skeletal muscle, heart, brain, and various other organs, presenting a complex challenge for treatment. Through its GeneTAC platform, Design Therapeutics, Inc. aims to develop a therapy that not only addresses the symptoms but also the underlying genetic causes of this debilitating disease.
Focusing on genetic eye diseases, Design Therapeutics, Inc. is also developing a therapeutic candidate for Fuchs Endothelial Corneal Dystrophy. This bilateral degenerative condition affects corneal endothelial cells, leading to progressive vision loss. Given the genetic basis of this disease, the company’s approach seeks to provide a significant therapeutic advancement, aiming at the correction of the underlying genetic faults to halt or potentially reverse the disease's progression.
Among its various innovative pursuits, Design Therapeutics, Inc. has also directed its resources towards the development of a therapy for Huntington's Disease. This dominantly inherited, monogenic condition leads to severe neurodegenerative issues, manifesting in movement, cognitive, and psychiatric disorders. Leveraging the GeneTAC platform, the company is on the forefront of creating a therapeutic approach that could potentially offer a disease-modifying treatment, addressing not just the symptoms but the genetic origin of Huntington's Disease.
